ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. reduced its stake in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 4.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 225,302 shares of the company’s stock after selling 10,718 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.43% of ALX Oncology worth $410,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of ALX Oncology by 207.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 83,042 shares of the company’s stock worth $151,000 after acquiring an additional 56,028 shares during the last quarter. GSA Capital Partners LLP acquired a new position in ALX Oncology during the 3rd quarter valued at about $88,000. Los Angeles Capital Management LLC bought a new position in ALX Oncology in the 3rd quarter worth about $469,000. Privium Fund Management B.V. increased its stake in shares of ALX Oncology by 28.2% in the third quarter. Privium Fund Management B.V. now owns 509,059 shares of the company’s stock valued at $926,000 after purchasing an additional 112,093 shares during the period. Finally, SG Americas Securities LLC raised its holdings in shares of ALX Oncology by 33.6% during the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after buying an additional 6,888 shares during the last quarter. 97.97% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other ALX Oncology news, Director Rekha Hemrajani acquired 30,000 shares of ALX Oncology stock in a transaction dated Monday, December 2nd. The stock was bought at an average price of $1.55 per share, for a total transaction of $46,500.00. Following the transaction, the director now owns 33,000 shares in the company, valued at approximately $51,150. This trade represents a 1,000.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. 33.40% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on ALXO shares. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of ALX Oncology in a report on Wednesday. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a research note on Wednesday. Finally, Jefferies Financial Group lowered ALX Oncology from a “buy” rating to a “hold” rating and lowered their price target for the company from $12.00 to $2.00 in a report on Thursday. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $8.50.

ALX Oncology Price Performance

Shares of NASDAQ:ALXO opened at $1.48 on Friday. The stock has a market cap of $78.06 million, a price-to-earnings ratio of -0.50 and a beta of 1.04. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. ALX Oncology Holdings Inc. has a 12 month low of $1.19 and a 12 month high of $17.83. The stock’s 50 day moving average price is $1.49 and its 200 day moving average price is $3.37.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.